BioStem Aligns with FDA's 'Leap Forward' in Clinical Trial Statistics

POMPANO BEACH, Fla. – February 03, 2026 – By Nancy Torres

A recent signal from the U.S. Food and Drug Administration (FDA) endorsing more flexible and powerful statistical methods is creating ripples across the medical technology landscape, and few are feeling the validation more strongly than BioStem Technologies. The Pompano Beach-based MedTech firm is highlighting the FDA’s growing openness to Bayesian statistical approaches, a move that directly bolsters the advanced methodology used in the company’s own clinical research for advanced wound care products.

The development comes as FDA leadership, including comments attributed to prominent figures like Dr. Martin Makary, described the agency’s evolving stance on Bayesian methods as a “leap forward” for clinical science. This shift promises to modernize how new therapies are evaluated, potentially making clinical trials more efficient, insightful, and ultimately, faster at delivering innovation to patients. For companies like BioStem, it’s a sign that the regulatory environment is catching up to the cutting edge of data science.

“This is an important and very positive signal from FDA leadership validating the advanced statistical analysis model used in our recently published peer reviewed randomized controlled trial that demonstrates superior outcomes with BioRetain® - processed allografts in diabetic foot ulcers,” said Jason Matuszewski, CEO and Chairman of BioStem Technologies, in a recent statement.

The FDA's Statistical Modernization

The FDA's encouragement is not just talk; it's formalized in recent regulatory guidance. In January 2026, the agency released a draft guidance titled "Use of Bayesian Methodology in Clinical Trials of Drugs and Biological Products." This document fulfills a commitment made under the Prescription Drug User Fee Act VII (PDUFA VII) and signals a significant step toward formally integrating these methods into the development pipeline for drugs and biologics, building on similar guidance issued for medical devices back in 2018.

Traditional clinical trials often rely on frequentist statistics, which can require large patient groups and rigid study designs to prove whether a treatment works. Bayesian statistics, in contrast, offer a more flexible framework. They allow researchers to incorporate prior knowledge—such as data from earlier studies or established biological principles—alongside new data gathered during a trial. This creates a constantly updating model that expresses outcomes in terms of probabilities, such as the likelihood that a treatment is effective.

The FDA notes that this approach can improve trial efficiency, optimize dosing, and better integrate early-phase data into later-stage studies. For challenging areas like rare diseases, where recruiting large numbers of patients is difficult, Bayesian methods can make a crucial difference. According to Zwelithini Tunyiswa, CEO of Open Wound Research, “FDA Commissioner Makary’s endorsement of Bayesian methods is a welcome recognition of the value these approaches bring to data analysis, synthesis, and planning. Bayesian methods ​allow for innovative designs, and more efficient use of time and resources through the principled incorporation of prior information and sequential learning.”

Validating a New Approach to Wound Healing

BioStem Technologies has positioned itself at the forefront of this statistical revolution. The company’s confidence stems from its application of these very methods in its own research. A study published in the International Wound Journal in October 2024 evaluated the effectiveness of its BioRetain-processed amnion/chorion membrane in treating diabetic foot ulcers (DFUs), one of the most challenging and debilitating chronic wounds.

While the company's press release referenced a randomized controlled trial, the published study was a retrospective cohort analysis that leveraged sophisticated Bayesian regression and hurdle modeling. This approach allowed researchers to move beyond simple binary endpoints—like whether a wound closed or not—to quantify more nuanced outcomes. The analysis revealed that patients treated with the BioRetain-processed allograft were not only more likely to achieve complete, lasting closure but also showed significantly greater wound size reduction even if full closure wasn't reached.

Specifically, the study, which focused on a real-world population with large and hard-to-heal wounds often excluded from typical trials, found the BioRetain-processed allograft arm was almost twice as likely to achieve lasting wound closure compared to standard of care. This degree of rigor, targeting the most difficult patient cases and adhering to strict 2006 FDA closure definitions, adds significant weight to the findings.

“We believe incorporating these metrics into clinical studies enables more efficient discovery; and in terms of our study, helps clinicians better understand the real-world complex wound healing performance of our products,” Matuszewski explained.

A Strategic Edge in a Competitive Market

The embrace of advanced statistics is more than an academic exercise; it’s a core business strategy. The advanced wound care market is a multi-billion-dollar industry, projected to reach nearly $18 billion by 2032. It’s a field dominated by large, established players, and smaller innovators like BioStem must rely on superior technology and evidence to compete.

By pioneering the use of Bayesian methods, BioStem gains a potential advantage. The detailed, probabilistic evidence generated from these analyses can create a more compelling case for physicians, health systems, and insurers. As Matuszewski noted, “These approaches allow us to generate the kind of clinically meaningful insights that physicians, health systems, and policymakers actually need.” This is particularly true in regenerative medicine and wound care, where patient responses can vary widely and real-world evidence is paramount.

This statistical validation complements BioStem’s recent strategic growth. In a significant move, the company just acquired BioTissue Holdings' surgical and wound care business, bringing the established Neox® and Clarix® product lines into its portfolio. The acquisition, which generated approximately $29 million in sales in 2025, provides BioStem with an immediate and substantial foothold in hospitals, diversifying its market presence beyond its traditional base.

With ongoing randomized controlled trials for both Diabetic Foot Ulcers and Venous Leg Ulcers expected to incorporate similar Bayesian analysis, the company is building a deep well of high-quality evidence. This commitment to rigorous, modern research methods, now aligned with the FDA’s forward-looking stance, could be the key to unlocking the full clinical and commercial potential of its proprietary BioRetain® and CryoTek® technologies, helping to accelerate the availability of more effective treatments for patients suffering from chronic wounds.